Current Processes Among National Cancer Institute Community Oncology Research Program Practices Cancer-associated cachexia is a multifaceted syndrome marked by severe weight loss, anorexia, muscle and ...

Cachexia is a metabolic syndrome characterized by the loss of body fat and muscle mass and affects about 50%–80% of cancer patients. The condition results in a deterioration in quality of life ...

The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer ...

View Full Profile. Learn about our Editorial Policies. Cancer cachexia, or the wasting syndrome, is a catastrophic condition that causes dramatic and involuntary loss of muscle mass, fat and weight, ...

Researchers at the Garvan Institute of Medical Research have uncovered how pancreatic cancer hijacks a crucial metabolism ...

Scientists at the Garvan Institute of Medical Research have found that pancreatic cancer uses a key metabolic switch to help ...

Researchers at the Garvan Institute of Medical Research have uncovered how pancreatic cancer hijacks a crucial metabolism ...

A new study has found over sixty per cent of women undergoing Cervical Cancer treatment at the Uganda Cancer Institute (UCI) ...

The global cancer cachexia market size is projected to reach $3.76 billion by 2032. This will be a huge market opportunity, especially since this is a huge unmet medical need. How so? There are no ...

Indeed, the next era of blockbuster cancer therapeutics could be focused on treating what ends up being the cause of death for up to 40% of cancer patients – cachexia. Historically, cachexia has ...

This discovery could lead to innovative treatments for conditions like aging, cancer cachexia, and obesity-related muscle loss while opening new doors for weight management strategies. However ...